Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir

Journal of Infectious Diseases

Volumn 176, Issue 1, 1997, Pages 50-58

  Jabs, Douglas A ^a   Jacobson, Mark ^b  

^a SOCA Chairman's Office   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOSCARNET; GANCICLOVIR; VIRUS DNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BLOOD CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INFECTION RISK; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINITIS; TREATMENT OUTCOME; URINE CULTURE; VIRUS CULTURE; VIRUS ISOLATION;

EID: 16944365122     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514039     Document Type: Article

References (27)

1. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. J Infect Dis 1992;166:1223-7.
2. Hoover DR, Saah AJ, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993;329:1922-6.
3. Bloom JN, Palestine AG. The diagnosis of cytomegalovirus retinitis. Ann Intern Med 1988;109:963-9.
4. Reichert CM, O'Leary TJ, Levens DL, Simrell CR, Macher AM. Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol 1983;12:357-82.
5. Collaborative DHPG Treatment Study Group. Treatment of serious cytomegalovirus infections with 9-(1,3-dihydroxy-2-propoxymethyl)guanine in patients with AIDS and other immunodeficiencies. N Engl J Med 1986;314:801-5.
6. Jacobson MA, O'Donnell JJ, Mills J. Foscarnet treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Antimicrob Agents Chemother 1989;33:736-41.
7. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992;326:213-20.
8. Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-ganciclovir cytomegalovirus retinitis trial - 1. Rationale, design, and methods. Control Clin Trial 1992;12:22-39.
9. Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trials Group (ACTG). Foscarnet-ganciclovir CMV retinitis trial. 4. Visual outcomes. Ophthalmology 1994;101:1250-61.
10. Studies of Ocular Complications of AIDS (SOCA) Research Group in collaboration with the AIDS Clinical Trial Group (ACTG). Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Arch Intern Med 1995;155:65-74.
11. Drew WL, Miner R, Saleh E. Antiviral susceptibility testing of cytomegalovirus: criteria for detecting resistance to antivirals. Clin Diagn Virol 1993;1:179-85.
12. Liang KY, Zeger SL. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-30.
13. Lipsitz SL, Harrington DP. Analyzing correlated binary data using SAS. Comput Biomed Res 1990;23:268-82.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Peto R, Peto J. Asymptotically efficient rank invariant test procedure. J R Stat Soc A 1972;135:185-207.
16. Brookmeyer R, Crowley J. A confidence interval for median survival time. Biometrics 1982;38:29-41.
17. Lee ET. Statistical methods for survival data analysis. 1st ed. Belmont, CA: Lifetime Learning Publications, 1980:232.
18. Cox DR. Regression models and life-tables. J R Stat Soc B 1972;34:187-220.
19. SAS/STAT software. The PHREG Procedure. Version 6. Cary, NC: SAS Institute, 1991:127.
20. Drew WL, Miner RC, Busch DF, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
21. Skolnick PR, Kosloff BR, Hirsch MS, et al. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. J Infect Dis 1988;157:508-14.
22. Webster A, Cook DG, Emery VC, et al. Cytomegalovirus infection and progression towards AIDS in hemophiliacs with human immunodeficiency virus infection. Lancet 1989;2:63-5.
23. Bonetti A, Weber R, Vogt MW, Wunderli W, Siegenthaler W, Luthy R. Co-infection with human immunodeficiency virus-type 1 (HIV-1) and cytomegalovirus in two intravenous drug users. Ann Intern Med 1989;111:293-6.
24. Chou S, Guentzel S, Michels KR, Miner RC, Drew WL. Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. J Infect Dis 1995;172:239-42.
25. Baldanti F, Underwood MR, Stanat SC, et al. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996;70:1390-5.
26. Jacobson MA, Drew WL, Feinberg J, et al. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. J Infect Dis 1991;163:1348-51.
27. Erice A, Chou S, Biron KK, Stanat SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.